Drug Trial Radar · NCT05215340
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
740
Actual
Start
Mar 4, 2022
Primary completion
Mar 4, 2030
Study completion Mar 4, 2032
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- Collaborators
- AstraZeneca; Merck Sharp & Dohme LLC
- First posted
- Jan 31, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab alone in participants with advanced or metastatic non-small cell lung cancer (NSCLC).
Conditions
- Metastatic Non Small Cell Lung Cancer
Interventions
Datopotamab DeruxtecanDrug
Dato-DXd will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
PembrolizumabDrug
Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival Based on Blinded Independent Central Review in Participants With Non-Squamous Histology Who Were Administered Dato-DXd in Combination With Pembrolizumab Compared With PembrolizumabTime frame: From randomization until disease progression or death (whichever occurs first), up to approximately 46 months
- Overall Survival (OS) in Participants With Non-Squamous Histology Who Were Administered Dato-DXd in Combination With Pembrolizumab Compared With PembrolizumabTime frame: From randomization until date of death due to any cause, up to approximately 72 months
Locations
234 sites in 28 countries. Site status is shown where the registry gives one.
Ironwood Cancer and Research Center
Chandler, Arizona
UCLA HemOnc - Clinical Research Unit
Los Angeles, California
Ridley-Tree Cancer Center
Santa Barbara, California
PIH Health Whittier Hospital
Whittier, California
The Oncology Institute of Hope and Innovation
Whittier, California
Uch-Mhs D/B/A Memorial Health System
Colorado Springs, Colorado
Johns Hopkins University
Baltimore, Maryland
American Oncology Partners of Maryland
Bethesda, Maryland
Dana-Farber Cancer Institute
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dana Farber Cancer Institute - Foxborough
Foxborough, Massachusetts
DFCI - South Shore Hospital
South Weymouth, Massachusetts
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire
Astera Cancer Care
East Brunswick, New Jersey
Regional Cancer Care Associates LLC
Freehold, New Jersey
Cooperman Barnabas Medical Center
New Brunswick, New Jersey
The Valley Hospital
Paramus, New Jersey
Montefiore Medical Center
The Bronx, New York
Arizona Oncology NAHOA
Irving, Texas
Cancer Care Center of Brevard
Irving, Texas
Illinois Cancer Specialists
Irving, Texas
Maryland Oncology Hematology
Irving, Texas
Southern Cancer Center
Irving, Texas
Texas Oncology - Northeast Texas
Irving, Texas
Texas Oncology Gulf Coast
Irving, Texas
Texas Oncology McAllen
Irving, Texas
University of Texas Health Science Center San Antonio
San Antonio, Texas
Utah Cancer Specialists
Salt Lake City, Utah
Providence Regional Cancer System
Lacey, Washington
VA Puget Sound Health Care System - VAPSHCS
Seattle, Washington
Medical College of Wisconsin
Milwaukee, Wisconsin
Centro de Investigaciones Medicas y Desarrollo LC S.R.L. (LC Investigacion)
Buenos Aires, Argentina
Fundacion CENIT para la investigación en Neurociencias
Ciudad Autonoma de Buenos Aire, Argentina
Hospital Privado de la Comunidad
Mar del Plata, Argentina
Centro de Investigación Pergamino S. A.
Pergamino, Argentina
Instituto de Oncología de Rosario
Rosario, Argentina
Sanatorio Parque
Rosario, Argentina
Sanatorio Británico de Rosario
Rosario, Argentina
CER SAN JUAN - Centro Polivalente de Asistencia e Investigación Clínica
San Juan, Argentina
Clinica Viedma SA
Viedma, Argentina
Showing 40 of 234 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.